Your browser doesn't support javascript.
loading
Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study.
Mohan, Divya; Forman, Julia R; Allinder, Matthew; McEniery, Carmel M; Bolton, Charlotte Emma; Cockcroft, John R; MacNee, William; Fuld, Jonathan; Marchong, Mellone; Gale, Nichola Sian; Fisk, Marie; Nagarajan, Sridevi; Cheriyan, Joseph; Lomas, David A; Calverley, Peter M A; Miller, Bruce E; Tal-Singer, Ruth; Wilkinson, Ian B; Polkey, Michael I.
Afiliação
  • Mohan D; NIHR Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, Imperial College, London, UK.
  • Forman JR; R&D, GlaxoSmithKline King of Prussia, Philadelphia, Pennsylvania, USA.
  • Allinder M; Division of Experimental Medicine and Immunotherapeutics, Cambridge Clinical Trials Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
  • McEniery CM; R&D, GlaxoSmithKline King of Prussia, Philadelphia, Pennsylvania, USA.
  • Bolton CE; Division of Experimental Medicine and Immunotherapeutics, Cambridge Clinical Trials Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
  • Cockcroft JR; Nottingham Respiratory Research Unit, NIHR Nottingham BRC, School of Medicine, City Hospital NUH Trust Campus, University of Nottingham, Nottingham, UK.
  • MacNee W; Department of Cardiology, Wales Heart Research Institute, Cardiff University, Cardiff, UK.
  • Fuld J; MRC Centre for Inflammation, University of Edinburgh, Edinburgh, UK.
  • Marchong M; Division of Experimental Medicine and Immunotherapeutics, Cambridge Clinical Trials Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
  • Gale NS; Division of Experimental Medicine and Immunotherapeutics, Cambridge Clinical Trials Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
  • Fisk M; Department of Cardiology, Wales Heart Research Institute, Cardiff University, Cardiff, UK.
  • Nagarajan S; Division of Experimental Medicine and Immunotherapeutics, Cambridge Clinical Trials Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
  • Cheriyan J; Division of Experimental Medicine and Immunotherapeutics, Cambridge Clinical Trials Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
  • Lomas DA; Division of Experimental Medicine and Immunotherapeutics, Cambridge Clinical Trials Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
  • Calverley PMA; Division of Medicine, UCL Respiratory, University College London, London, UK.
  • Miller BE; School of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
  • Tal-Singer R; R&D, GlaxoSmithKline King of Prussia, Philadelphia, Pennsylvania, USA.
  • Wilkinson IB; R&D, GlaxoSmithKline King of Prussia, Philadelphia, Pennsylvania, USA.
  • Polkey MI; Division of Experimental Medicine and Immunotherapeutics, Cambridge Clinical Trials Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Thorax ; 73(12): 1182-1185, 2018 12.
Article em En | MEDLINE | ID: mdl-29618495
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrinogênio / Debilidade Muscular / Doença Pulmonar Obstrutiva Crônica / Rigidez Vascular Idioma: En Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrinogênio / Debilidade Muscular / Doença Pulmonar Obstrutiva Crônica / Rigidez Vascular Idioma: En Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido